ReviewJournal of diabetes and metabolic disorders2026
AMPK as a central regulator of metabolic memory: mechanisms and therapeutic opportunities.
Review in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Exercise Is Associated with Skeletal Muscle Autophagy-Lysosome-Related Markers and Nrf2/ARF1 Signaling in HFD Mice.Nutrients · 2026Article
- Mitochondrial Dysfunction in Renal Proximal Tubule Injury: Mechanisms, Pathophysiology, and Therapeutic Opportunities.The Yale journal of biology and medicine · 2026Review
- The effect of opioids on the blood glucose level and lipid profile: a systematic review and meta-analysis.Journal of diabetes and metabolic disorders · 2026Review
- Crosstalk between gut microbiota and RNA N6-methyladenosine modification in diabetic retinopathy.Frontiers in cell and developmental biology · 2026Review
- Advancing the frontiers of phytotherapy: a comprehensive review of botanical interventions targeting mitochondrial quality control to ameliorate endometriosis.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenosine monophosphate-activated protein kinase (AMPK) is a conserved serine/threonine kinase that acts as a central regulator of cellular energy homeostasis. Activated by an elevated AMP/ATP or ADP/ATP ratio under energy-depleting conditions such as exercise, caloric restriction, or hypoxia, AMPK shifts cellular metabolism by promoting catabolic pathways (e.g., fatty acid oxidation, autophagy) and inhibiting anabolic processes (e.g., lipid and protein synthesis) to restore energy balance. Beyond its classical metabolic role, AMPK also influences epigenetic regulation, mitochondrial biogenesis, and oxidative stress responses-key components implicated in metabolic memory, a phenomenon where transient hyperglycemia induces lasting cellular dysfunction. This persistent "memory" contributes to chronic diabetic complications, including nephropathy, retinopathy, cardiomyopathy, and impaired wound healing. AMPK activation has been shown to mitigate these effects by inhibiting NF-κB-driven inflammation, enhancing SIRT1-PGC-1α-mediated mitochondrial function, and reversing hyperglycemia-induced histone modifications and DNA methylation. Both synthetic activators (e.g., metformin, AICAR, A769662) and natural compounds (e.g., resveratrol, berberine, curcumin) have demonstrated the ability to restore metabolic balance and improve insulin sensitivity in preclinical models. However, challenges persist regarding the long-term safety, bioavailability, and tissue specificity of these agents. This review explores the multifaceted roles of AMPK in metabolic regulation and its emerging therapeutic potential in countering metabolic memory. A deeper understanding of AMPK signaling pathways may enable the development of targeted interventions to prevent or reverse the long-term complications of diabetes and other metabolic disorders. Graphical abstract:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.